ARTICLE | Deals
Small molecule program, now in Phase II, could challenge injectable blockbuster; joins IBD drug Omvoh in pharma’s immunology arsenal
By Paul Bonanos, Director of Biopharma Intelligence
July 8, 2024 10:53 PM UTC
Lilly’s takeout of Morphic gives it an oral integrin program that complements its recently approved IBD drug with a different mechanism, and could compete directly with an established, injectable blockbuster in its own class.
The $3.2 billion deal for nine-year-old Morphic Holding Inc. (NASDAQ:MORF) gives Eli Lilly and Co. (NYSE:LLY) MORF-057, a molecule targeting integrin α4β7 that is in two Phase II trials to treat ulcerative colitis and one Phase II study for Crohn’s disease…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652906/via-3-2b-morphic-deal-lilly-gets-oral-integrin-to-compete-in-entyvio-s-class